Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis

Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis

Interleukin (IL)-1β is a potent inhibitor of gastric acid secretion and its genetic polymorphism is linked to the severity of reflux esophagitis. Proton-pump inhibitor (PPI) metabolized by P450 2C19 (CYP2C19) is the chief medication in reflux esophagitis treatment. The CYP2C19 genotype may influence...

Full description

Bibliographic Details
Main Authors: Wen-Hung Hsu, Fu-Chen Kuo, Huang-Ming Hu, Ping-I Hsu, Deng-Chyang Wu, Chao-Hung Kuo
Format: Article
Language:English
Published: Wiley 2015-05-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
CYP2C19
Genetic polymorphism
Interleukin-1β
Proton pump inhibitor
Reflux esophagitis
Online Access:http://www.sciencedirect.com/science/article/pii/S1607551X15000224

Similar Items

Similar Items